Caris Discovery
Let Caris help you unlock truly novel and otherwise inaccessible targets for your discovery pipeline.
Highly differentiated, orthogonal multi-omics method for target discovery
Adaptive dynamic artificial polyligand targeting (ADAPT)
Unbiased target ID platform that uses a broad library of aptamers to profile biological samples at a systems-wide scale
Repository of over 9M+ FFPE slides across oncology
Unparalleled data and robust validation pipeline
WES and WTS: full coverage DNA & RNA molecular information paired to clinical outcomes data
State of the art equipment and facilities: 45 NovaSeqs, 300K+ Sq. Ft., dedicated Caris Discovery wet lab
Differentiation and aggregate strength of the Caris platform unlocks otherwise inaccessible target discovery opportunities
-
22,000
encoding DNA genes
-
61,000
RNA transcripts
-
400K+
molecular tumor profiles
-
275K+
profiles with matched clinical data
-
9M+
slides
-
1 Trillion
daily "reads" capacity
-
ADAPT
aptamer biotargeting system
-
Proximity Labeling
multi-specific interactions
-
Cell Surfaceome
>3,000 proteins identified
-
Sensitivity & Specificity
antibodies IHC & flow cytometry
-
Target Expression
normal vs. cancer tissue
-
60+
POA leading cancer institutions
-
56
countries with presence
-
300+
specialized oncology salesforce
-
300K+
sq. ft. of lab space
-
4
precision medicine labs
unparalleled data
innovation lab
broad footprint
Note: Data current as of August 1, 2022
unparalleled data
-
22,000
encoding DNA genes
-
61,000
RNA transcripts
-
400K+
molecular tumor profiles
-
275K+
profiles with matched clinical data
-
9M+
slides
-
1 Trillion
daily "reads" capacity
innovation lab
-
ADAPT
aptamer biotargeting system
-
Proximity Labeling
multi-spcific interactions
-
Cell Surfaceome
>3,000 proteins identified
-
Sensitivity & Specificity
antibodies IHC & flow cytometry
-
Target Expression
normal vs. cancer tissue
broad footprint
-
60+
POA leading cancer institutions
-
56
countries with presence
-
300+
specialized oncology salesforce
-
300K+
sq. ft. of lab space
-
4
precision medicine labs
Note: Data current as of August 1, 2022
State of the art equipment and facilities for target ID and drug development
Footprint of 45 NovaSeqs
- Leading high throughput oncology profiling lab for NovaSeqs in U.S.
- Improvements in throughput efficiencies
- Enhanced depth of coverage
4 Precision Medicine Laboratories (Phoenix and Dallas) Totaling 300K+ Sq. Ft.
Clinical
Tissue Lab
(Cotton Center,
Phoenix, AZ)
Drug Target Discovery Lab
(Papago,
Phoenix, AZ)
Clinical Blood Lab
(Cotton Center,
Phoenix, AZ)
Coming Soon -
Clinical Tissue & Blood Lab
(Irving, TX)
AI technology enabled platform for target discovery agnostic to treatment modality
Antibody-drug conjugates (ADCs), multi-specifics, radiopharmaceuticals, cell therapies, small molecules, degraders, and others
Druggable Genome
10K+ Candidates
Disease Prevalence / Specificity & RWE
1,000 Candidates
Protein Target Validation
100 – 1,000 Candidates